West Pharmaceutical Services (WST) Stock Forecast & Price Target $392.00 -2.03 (-0.52%) Closing price 10/23/2026 03:59 PM EasternExtended Trading$396.52 +4.53 (+1.16%) As of 10/23/2026 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest West Pharmaceutical Services - Analysts' Recommendations and Stock Price Forecast (2026) How MarketBeat Calculates Price Target and Consensus Rating Consensus Rating Moderate BuyBased on 14 Analyst RatingsSell0Hold2Buy12 Based on 14 Wall Street analysts who have issued ratings for West Pharmaceutical Services in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 14 analysts, 2 have given a hold rating, and 12 have given a buy rating for WST. Consensus Price Target $391.17-0.21% Downside According to the 14 analysts' twelve-month price targets for West Pharmaceutical Services, the average price target is $391.17. The highest price target for WST is $447.00, while the lowest price target for WST is $295.00. The average price target represents a forecasted downside of -0.21% from the current price of $392.00. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Get the Latest News and Ratings for WST and Related Stocks Enter your email address to receive the latest news and analysts' ratings for West Pharmaceutical Services and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. WST Analyst Ratings Over TimeTypeCurrent Forecast10/25/25 to 10/25/261 Month Ago9/25/25 to 9/25/263 Months Ago7/27/25 to 7/27/261 Year Ago10/25/24 to 10/25/25Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)2 Strong Buy rating(s)2 Strong Buy rating(s)Buy12 Buy rating(s)12 Buy rating(s)11 Buy rating(s)6 Buy rating(s)Hold2 Hold rating(s)2 Hold rating(s)2 Hold rating(s)4 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)Consensus Price Target$391.17$382.00$363.17$347.63Forecasted Upside-0.21% Downside3.07% Upside9.54% Upside16.60% UpsideConsensus RatingModerate BuyModerate BuyBuyModerate Buy WST Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History WST Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table West Pharmaceutical Services Stock vs. The CompetitionTypeWest Pharmaceutical ServicesHealthcare CompaniesBroader MarketConsensus Rating Score 2.86 2.32 2.53Consensus RatingModerate BuyHoldModerate BuyPredicted Upside-0.21% Downside1,400.11% Upside16.92% UpsideNews Sentiment RatingPositive NewsSee Recent WST NewsNeutral NewsPositive News Recent Analyst Forecasts and Stock Ratings Most Recent from Each Brokerage All Show All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action 10/25/2024 - 10/25/2026 Report Date Report Date From Report Date To 1M3M6MYTD1Y2Y3Y5Y More filters Fewer filters Done 0 Results Export DateBrokerageAnalystActionRatingPrice TargetReport Date Upside/DownsideDetails10/13/2026 TD Cowen3 of 5 starsBrendan SmithNot RatedBoost TargetBuy$410.00 ➝ $420.00+13.94%10/7/2026 Barclays3 of 5 starsLuke Sergott5 of 5 starsBoost TargetOverweight$400.00 ➝ $440.00+17.97%9/22/2026 Morgan Stanley3 of 5 starsKallum TitchmarshNot RatedUpgradeEqual Weight ➝ Overweight$365.00 ➝ $400.00+10.59%9/9/2026 UBS GroupSubscribe to MarketBeat All Access to unlock brokerage rankingsDoug SchenkelSubscribe to MarketBeat All Access to unlock analyst rankingsBoost TargetBuy$340.00 ➝ $415.00+22.22%8/12/2026 Zacks ResearchSubscribe to MarketBeat All Access to unlock brokerage rankings DowngradeStrong-Buy ➝ Hold8/7/2026 Weiss RatingsSubscribe to MarketBeat All Access to unlock brokerage rankings UpgradeHold (C) ➝ Hold (C+)8/3/2026 CitigroupSubscribe to MarketBeat All Access to unlock brokerage rankingsJoanne WuenschSubscribe to MarketBeat All Access to unlock analyst rankingsBoost TargetBuy$400.00 ➝ $412.00+20.81%7/27/2026 EvercoreSubscribe to MarketBeat All Access to unlock brokerage rankingsDaniel MarkowitzSubscribe to MarketBeat All Access to unlock analyst rankingsReiterated RatingOutperform$425.00+28.46%7/13/2026 BNP Paribas ExaneSubscribe to MarketBeat All Access to unlock brokerage rankingsCurtis MoilesSubscribe to MarketBeat All Access to unlock analyst rankingsInitiated CoverageOutperform$447.00+26.38%7/2/2026 KeyCorpSubscribe to MarketBeat All Access to unlock brokerage rankingsPaul KnightSubscribe to MarketBeat All Access to unlock analyst rankingsBoost TargetOverweight$350.00 ➝ $390.00+6.84% Get the Latest News and Ratings for WST and Related StocksEnter your email address below to receive the latest news and analysts' ratings for West Pharmaceutical Services and its competitors with MarketBeat's FREE daily newsletter. 6/2/2026 StephensSubscribe to MarketBeat All Access to unlock brokerage rankingsSteven EtochSubscribe to MarketBeat All Access to unlock analyst rankingsReiterated RatingOverweight$360.00+13.97%6/1/2026 Wolfe ResearchSubscribe to MarketBeat All Access to unlock brokerage rankingsMike PolarkSubscribe to MarketBeat All Access to unlock analyst rankingsInitiated CoverageOutperform$375.00+18.72%2/13/2026 Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access to unlock brokerage rankingsJustin BowersSubscribe to MarketBeat All Access to unlock analyst rankingsReiterated RatingBuy$315.00+29.70%2/10/2026 Jefferies Financial GroupSubscribe to MarketBeat All Access to unlock brokerage rankingsDavid WindleySubscribe to MarketBeat All Access to unlock analyst rankingsReiterated RatingBuy$295.00+17.85%9/15/2025 Rothschild & Co RedburnSubscribe to MarketBeat All Access to unlock brokerage rankingsJamie ClarkSubscribe to MarketBeat All Access to unlock analyst rankingsSet Target$311.00+20.67%12/13/2024 Bank of AmericaSubscribe to MarketBeat All Access to unlock brokerage rankings Boost TargetBuy$350.00 ➝ $355.00+8.95%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 05:44 PM ET. Should I Buy West Pharmaceutical Services Stock? WST Pros and Cons Explained These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, October 24, 2026. Please send any questions or comments about these West Pharmaceutical Services pros and cons to contact@marketbeat.com. West Pharmaceutical Services Bull Case Here are some ways that investors could benefit from investing in West Pharmaceutical Services, Inc.: West Pharmaceutical Services, Inc. recently declared a quarterly dividend of $0.26 per share, representing an 18.2% increase from the previous quarter's $0.22 payment, marking the thirty-fourth consecutive annual increase in the company's dividend payout. The company demonstrated strong financial performance in its most recent quarterly report, with revenue of $872.30 million exceeding analyst estimates of $839.98 million and earnings per share of $2.37 beating the consensus estimate of $2.08, indicating robust demand for its pharmaceutical packaging components. West Pharmaceutical Services, Inc. has raised its full-year 2026 earnings per share guidance to a range of $8.85 to $9.05, which is significantly higher than the consensus estimate of $8.61, suggesting management confidence in continued growth and operational efficiency. Institutional investors are showing renewed interest in the stock, with Robeco Institutional Asset Management B.V. increasing its stake by 75.2% during the third quarter, signaling strong confidence from major asset managers in the company's long-term prospects. The stock is currently trading at $392.00, which is near its 52-week high of $397.15, reflecting a strong upward momentum and outperformance relative to its industry peers over the past year. West Pharmaceutical Services Bear Case Investors should be bearish about investing in West Pharmaceutical Services, Inc. for these reasons: Wall Street Zen recently downgraded West Pharmaceutical Services, Inc. from a "buy" rating to a "hold" rating, suggesting that some analysts believe the stock's recent gains may have priced in much of the positive news and that further upside is limited. The company's current price-to-earnings ratio of 46.14 is relatively high, which may indicate that the stock is overvalued compared to its historical averages or industry peers, potentially limiting future returns for new investors. Insider selling has been notable recently, with Vice President Annette Favorite selling a total of 15,659 shares over the last three months, which could signal that company executives are taking advantage of the stock's recent high prices to reduce their personal holdings. Some financial analyses suggest that West Pharmaceutical Services, Inc. stock could be 17% overvalued as cash flow falls short of expectations, raising concerns about the sustainability of its current valuation and future earnings growth. The stock's beta of 1.13 indicates that it is slightly more volatile than the overall market, meaning investors may experience greater price swings and higher risk compared to less volatile investments. WST Forecast - Frequently Asked Questions What is West Pharmaceutical Services' forecast for 2026? According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for West Pharmaceutical Services is $391.17, with a high forecast of $447.00 and a low forecast of $295.00. Should I buy or sell West Pharmaceutical Services stock right now? 14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for West Pharmaceutical Services in the last year. There are currently 2 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" WST shares. Does West Pharmaceutical Services's stock price have much downside? According to analysts, West Pharmaceutical Services's stock has a predicted downside of -0.21% based on their 12-month stock forecasts. Has West Pharmaceutical Services been upgraded or downgraded by Wall Street analysts recently? Over the previous 90 days, West Pharmaceutical Services's stock had 2 upgrades and 1 downgrade by analysts. What analysts cover West Pharmaceutical Services? West Pharmaceutical Services has been rated by research analysts at Barclays, Citigroup, Evercore, Morgan Stanley, TD Cowen, UBS Group, Weiss Ratings, and Zacks Research in the past 90 days. Do Wall Street analysts like West Pharmaceutical Services more than its competitors? Analysts like West Pharmaceutical Services more than other "healthcare" companies. The consensus rating for West Pharmaceutical Services is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how WST compares to other companies. Stock Forecasts and Research Tools Related Companies Chemed Stock Forecast Encompass Health Stock Forecast Medline Stock Forecast Alcon Stock Forecast Solventum Stock Forecast Cooper Companies Stock Forecast Align Technology Stock Forecast Bausch + Lomb Stock Forecast Merit Medical Systems Stock Forecast ICU Medical Stock Forecast Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Brokerages With West Pharmaceutical Services RecommendationsWall Street ZenTD CowenBarclaysMorgan StanleyUBS GroupZacks ResearchWeiss RatingsCitigroupEvercoreBNP Paribas ExaneKeyCorpStephensWolfe ResearchDeutsche Bank AktiengesellschaftJefferies Financial Group MarketBeat monitors more than a dozen sources for West Pharmaceutical Services analyst ratings, with the most recent rating issued on 10/13/2026. From Our Partners$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that l...Profits Run | SponsoredWhy tech stocks are deadAI skeptics see dot-com era warning signs, and they have a point. But the real opportunity may not be in the b...Porter & Company | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredCigar Lake Flooded Again Uranium Supply Shock RepeatsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...Digest Publishing | SponsoredAsk a 20 Year Trading Pro Your Stock Questions Live for 5Ross Givens, a market analyst with over 20 years on Wall Street, goes live every Monday at 9 AM ET to break do...Traders Agency | SponsoredThe data center backlash is creating a rare investing opportunityA new Gallup poll shows 70% of Americans want AI data centers kept out of their communities - and futurist Geo...Eagle Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding West Pharmaceutical Services, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share West Pharmaceutical Services With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.